Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur Jacques CORCOS

RPPS 10003969002
📊 Reconnaissance scientifique : 49/100📝 360 articles publiés📚 HAL (2)

✨ Profil synthétique

IA · 06/05/2026

Le Docteur Jacques CORCOS est un rhumatologue avec une production scientifique importante, comme en témoignent son h-index de 49 et ses 360 publications. Ses recherches portent principalement sur des sujets urologiques, bien que son profil professionnel soit celui d'un rhumatologue. Ses publications sur PubMed couvrent divers aspects, notamment les essais cliniques, la qualité de vie et les biomarqueurs.

Expertises présumées

  • Gériatrie rhumatologique
  • Épidémiologie des maladies rhumatismales
  • Biomarqueurs en rhumatologie
  • Essais cliniques en rhumatologie
  • Qualité de vie des patients rhumatismaux
  • Revue générale des maladies rhumatismales

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

📚 CES (Certificat d'Études Spéciales)

  • CES Rhumatologie

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

49

h articles cités ≥ h fois chacun. Un h de 49 = 49 publications avec 49+ citations.

Citations

7 245

Publications

360

i10-index

128

Thématiques principales

  • Urinary Bladder and Prostate Research ×185
  • Pelvic floor disorders treatments ×179
  • Urological Disorders and Treatments ×56
  • Urinary Tract Infections Management ×55
  • Bladder and Urothelial Cancer Treatments ×23
Voir sur OpenAlex ↗🆔 ORCID 0000-0002-0284-1300

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Bibliographie

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial

    The Journal of urology · 2011

    📚 106 citations🎯 RCR 4.90Top 8% NIH🩺 Clinique
  • 2
    PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer

    BJU international · 2011

    📚 92 citations🎯 RCR 2.25Top 23% NIH
    Lire l'abstract Crossref ↓

    What’s known on the subject? and What does the study add? So far we know that ERG rearrangements and PTEN deletions interact to induce prostate cancer in transgenic mice. The study confirms that an association also exists between the two genetic aberrations in human prostate cancer, as there is increased incidence of PTEN deletions in cases with ERG rearrangements. OBJECTIVE To investigate the interaction between, and significance of, ERG gene rearrangements and PTEN genomic deletions in relation to the development and progression of prostate cancer (PCA). PATIENTS AND METHODS We interrogated an initial cohort of 220 men with localized PCA using fluorescence in situ hybridization for ERG rearrangements and PTEN genomic deletions. RESULTS The incidences of ERG rearrangements and PTEN deletions in PCA were significantly higher than in high‐grade prostatic intra‐epithelial neoplasia (HGPIN) and benign prostate tissue ( P < 0.001). ERG rearrangements and PTEN deletions were detected in 41.9 and 42.6% of patients’ tumours, respectively. ERG rearrangements were never detected in benign prostate tissue, while PTEN aberrations were present at a basal level of 4.6%. PTEN hemizygous deletions showed higher frequency than homozygous deletions within each diagnostic category from benign prostate tissue to HGPIN and PCA ( P ≤ 0.001). Furthermore, in 29 patients where all three tissues were available, PTEN genomic aberrations in PCA were significantly different from those in benign tissue ( P = 0.005) and HGPIN ( P = 0.02), reflecting the accumulation of genomic aberrations in the early stages of disease progression. Within this cohort, 71.4% of homozygous and 44.2% of hemizygous PTEN deletions occurred simultaneously with ERG rearrangements ( P ≈ 0). Stratified according to Gleason score (GS), hemizygous PTEN deletions across various GS groups were observed at a higher frequency than homozygous deletions. However, PTEN homozygous deletions showed positive trends with higher GS, increasing in poorly differentiated PCA (GS 8–10) in comparison to moderately and well differentiated tumours (GS 6 and 7). CONCLUSION We show significant association between ERG gene rearrangements and PTEN genomic aberrations in subset of PCA. Our analysis also provides further support for the observation that homozygous PTEN deletions can occur within the subset of HGPIN lesions, and shows accumulating genetic aberrations with disease progression, evidenced by higher detection in PCA than in HGPIN and more PTEN homozygous deletions in GS 8–10 than in 6–7.

  • 3
    Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2017

    📚 64 citations🎯 RCR 4.05Top 11% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Multiple sclerosis (MS) is a unique neurological disease with a broad spectrum of clinical presentations that are time- and disease course-related. MS plaque location (intracranial and/or spinal) is a key feature in the pathophysiology of disease-related lower urinary tract symptoms (LUTS). The prevalence of these symptoms in MS patients is very high, with nearly 90% of them experiencing some degree of voiding dysfunction and/or incontinence. LUTS rarely present as primary MS manifestations and usually appear 6–8 years after the initial diagnosis. Symptom severity usually correlates with the disability status of patients. Patient assessment comprises clinical and advanced investigations. Each patient should be evaluated uniquely, after taking into account his/her symptoms, disease course and length, comorbidities, physical status, and medications. Basic investigation includes detailed history-taking, physical examination, and post-void residual volume measurement. Advanced evaluation consists of imaging and specific testing, with pivotal importance on urodynamic study.

Publications scientifiques (49) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal36

▼

Revue générale4

▼

Essai clinique2

▼

Qualité de vie / PROMs2

▼

Biomarqueurs / Auto-Ac1

▼

Épidémiologie & registres1

▼

Gériatrie1

▼

Santé mentale / fatigue1

▼

Vraie vie / RWE1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.